Karyopharm Therapeutics Inc
Statements
Ratios
Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.9 | 0.9 | 1.9 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2.1 | 1.8 | 3.0 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -55.9% | -42.7% | -23.0% | |
| Margins | ||||||||||||||||||||||||||||||||||||||||
| -57,451.6% | -48,482.7% | -40,091.9% | -52,771.7% | -76,853.7% | -6,571.4% | -979.0% | -365.0% | -396.8% | -431.9% | -671.2% | -1,285.2% | -353.8% | -63.6% | 49.5% | 95.6% | 96.7% | 97.5% | 97.5% | 96.5% | 96.9% | 98.4% | 98.3% | 98.5% | 98.4% | 96.7% | 96.5% | 96.3% | 96.4% | 96.6% | 96.0% | 95.9% | 95.7% | 95.7% | 96.1% | 96.4% | 95.9% | 95.9% | 96.0% | 95.9% | |
| -71,891.7% | -61,861.5% | -51,199.1% | -68,034.9% | -97,728.1% | -8,118.0% | -1,206.2% | -457.5% | -511.2% | -593.0% | -1,004.7% | -2,112.5% | -884.5% | -462.9% | -291.6% | -205.5% | -195.5% | -159.0% | -156.2% | -181.4% | -153.6% | -46.8% | -34.4% | -29.6% | -24.6% | -90.5% | -93.5% | -85.7% | -86.1% | -88.7% | -94.3% | -89.9% | -84.9% | -82.2% | -83.7% | -83.9% | -73.1% | -62.1% | -55.7% | -56.2% | |
| -71,138.9% | -61,216.2% | -50,646.4% | -67,267.5% | -96,594.2% | -8,021.4% | -1,191.7% | -451.2% | -502.9% | -588.1% | -1,005.9% | -2,138.8% | -909.2% | -488.1% | -316.5% | -228.4% | -221.2% | -181.6% | -177.3% | -203.2% | -173.8% | -59.1% | -46.1% | -41.2% | -35.3% | -105.2% | -106.7% | -97.0% | -95.8% | -98.0% | -104.2% | -61.7% | -58.9% | -52.6% | -44.0% | -90.0% | -87.4% | -134.2% | -129.0% | -153.3% | |
| -54,342.7% | -47,184.9% | -38,723.0% | -52,280.7% | -72,900.0% | -4,588.2% | -728.8% | -319.5% | -372.1% | -532.3% | -942.5% | -2,014.2% | -872.7% | -467.1% | -287.7% | -194.8% | -185.7% | -148.4% | -148.6% | -179.6% | -137.7% | -51.2% | -48.5% | -37.1% | -39.1% | -95.2% | -73.8% | -68.3% | -69.2% | -63.5% | -83.8% | -89.6% | -81.1% | -87.9% | -86.3% | -75.0% | -62.7% | -51.6% | -39.1% | -44.6% | |
| Returns | ||||||||||||||||||||||||||||||||||||||||
| -66.9% | -67.5% | -81.3% | -67.0% | -82.8% | -99.6% | -144.0% | -66.4% | -93.1% | -97.4% | -169.9% | -261.8% | -349.3% | -401.0% | -112.2% | -145.9% | -240.5% | -388.3% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -60.8% | -60.7% | -72.3% | -60.1% | -71.4% | -71.5% | -94.0% | -55.3% | -72.4% | -52.3% | -71.8% | -90.7% | -70.2% | -67.7% | -44.8% | -49.8% | -59.7% | -62.7% | -73.0% | -72.6% | -81.2% | -40.6% | -36.8% | -40.4% | -38.1% | -46.1% | -48.5% | -47.5% | -51.8% | -59.5% | -71.6% | -42.0% | -46.2% | -46.5% | -49.0% | -117.8% | -129.5% | -180.8% | -148.4% | -201.9% | |
| Balance Sheet & Debt | ||||||||||||||||||||||||||||||||||||||||
| -44 | -50 | -26 | -42 | -36 | -47 | -16 | -96 | -72 | 18 | 22 | 32 | -58 | -17 | -89 | 12 | 35 | 34 | 82 | 30 | 34 | -19 | 19 | 90 | 101 | 38 | 89 | 93 | 130 | 122 | 144 | 110 | 121 | 125 | 141 | 146 | 153 | 167 | 135 | 156 | |
| 90.9% | 89.9% | 89.0% | 89.8% | 86.2% | 71.8% | 65.3% | 83.2% | 77.8% | 53.7% | 42.2% | 34.6% | 20.1% | 16.9% | 39.9% | 34.2% | 24.8% | 16.1% | -14.4% | -29.0% | -49.6% | -26.1% | -28.3% | -45.4% | -60.7% | -4.7% | -13.9% | -23.9% | -37.2% | -56.6% | -82.6% | -61.8% | -84.3% | -113.1% | -161.2% | -227.8% | -279.8% | -270.2% | -202.1% | -296.6% | |
| 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.2 | 0.7 | 0.9 | 1.3 | 1.8 | 2.2 | 0.7 | 0.9 | 1.4 | 2.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| Per Share | ||||||||||||||||||||||||||||||||||||||||
| -45.50 | -39.72 | -40.26 | -36.55 | -37.19 | -39.77 | -41.59 | -37.92 | -39.42 | -2.94 | -50.80 | -53.14 | -50.53 | -3.12 | -41.34 | -38.79 | -41.14 | -2.66 | -40.41 | -41.48 | -40.99 | -21.43 | -20.90 | -19.50 | -16.47 | -27.57 | -1.39 | -18.60 | -18.33 | -18.70 | -19.01 | -8.73 | -10.50 | -9.11 | -7.38 | -14.33 | -14.38 | -10.76 | -7.89 | -7.77 | |
| 0.06 | 0.06 | 0.08 | 0.05 | 0.04 | 0.50 | 3.49 | 8.40 | 7.84 | 0.50 | 5.05 | 2.48 | 5.56 | 0.64 | 13.06 | 16.98 | 18.60 | 1.47 | 22.79 | 20.41 | 23.59 | 36.23 | 45.29 | 47.33 | 46.71 | 26.20 | 1.31 | 19.18 | 19.13 | 19.08 | 18.25 | 14.15 | 17.81 | 17.31 | 16.78 | 15.92 | 16.44 | 8.02 | 6.11 | 5.07 | |
| 68.01 | 58.82 | 49.54 | 54.56 | 44.92 | 39.92 | 28.89 | 57.09 | 42.36 | 3.01 | 29.89 | 20.30 | 14.46 | 0.78 | 36.85 | 26.58 | 17.10 | 0.69 | -7.98 | -16.58 | -25.04 | -13.76 | -16.07 | -21.91 | -26.23 | -2.78 | -0.40 | -9.36 | -13.16 | -17.80 | -21.95 | -12.84 | -19.16 | -22.17 | -24.31 | -27.72 | -31.06 | -16.08 | -10.75 | -11.41 | |
| -34.76 | -30.62 | -30.78 | -28.40 | -28.07 | -22.75 | -25.43 | -26.85 | -29.17 | -2.66 | -47.60 | -50.05 | -48.50 | -2.99 | -37.57 | -33.07 | -34.54 | -2.18 | -33.87 | -36.65 | -32.47 | -18.53 | -21.99 | -17.53 | -18.24 | -24.95 | -0.96 | -13.11 | -13.23 | -12.12 | -15.30 | -12.68 | -14.45 | -15.21 | -14.49 | -11.94 | -10.30 | -4.14 | -2.39 | -2.26 | |
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.